Plus   Neg

SLS To Report Data In 1H18, AVGR Slumps As Revenue Drops, DXR Down 45% In 3 Days

pharma down 032018 lt

The following are some of the stocks that lost the largest percentage in price today in the pharma/biotech sector.

1. AmpliPhi Biosciences Corporation (APHB)

Lost 21.43% to close Tuesday's (Mar.20) trading at $1.21.

News: The Company has entered into definitive purchase agreements with certain institutional investors to sell in a registered direct offering 2.74 million shares of its common stock at a price of $1.10 per share. The gross proceeds from this registered direct offering are expected to be approximately $3.0 million.

The offering is expected to close on or about March 22, 2018, subject to customary closing condition.

2. SELLAS Life Sciences Group Inc. (SLS)

Lost 18.53% to close Tuesday's trading at $3.87.

Recent news:

-- On March 19, 2018, the Company presented encouraging data from a phase II trial of its lead cancer immunotherapeutic candidate, Galinpepimut-S (GPS), in the treatment of high-risk multiple myeloma at the 44th Annual European Society for Blood and Marrow Transplantation (EBMT) Meeting. Safety results from the study were also presented.

The trial involved 19 patients with multiple myeloma who had high-risk cytogenetics at diagnosis and remained at least minimal residual disease (MRD)-positive after a successful autologous stem cell transplant ("ASCT").

Galinpepimut-S demonstrated a median progression-free survival (PFS) of 23.6 months in the high-risk disease setting, compared to historically inferior outcomes while on an immunomodulatory drug (IMID) or proteasome inhibitor post-ASCT maintenance.
Median overall survival has not been reached to date.

The other clinical programs are a phase I/II study of GPS in combination with Opdivo in Ovarian Cancer, and a phase II study of NEUVAX in combination with Herceptin, for HER2 1+/2+ breast cancers.

Near-term catalysts:

--- Interim data from GPS /Opdivo combination trial in ovarian cancer is expected in the first half of this year.
--- Interim data analysis of the phase II study of NEUVAX is scheduled for the first half of this year.

3. Avinger Inc. (AVGR)

Lost 17.99% to close Tuesday's trading at $1.14.

News: The Company announced results for the fourth quarter and full year ended December 31, 2017.

Net loss for the fourth quarter of 2017 narrowed to $10.2 million or $12.58 per share from $13.5 million or $23.35 per share for the fourth quarter of 2016.

Total revenue was $1.9 million for the fourth quarter ended December 31, 2017, a 59% decrease from the fourth quarter of 2016. Gross margin for the fourth quarter of 2017 was 9%, compared to 21% in the fourth quarter of 2016.

4. CHF Solutions Inc. (CHFS)

Lost 14.75% to close Tuesday's trading at $3.41.

The Company commercializes Aquadex FlexFlow system, indicated for ultrafiltration to reduce fluid overload in patients when diuretics fail. The device is FDA 510(k) market cleared and CE marked.

News: The Company announced financial results for the fourth quarter and year ended December 31, 2017.

Net sales for the fourth quarter of 2017 rose to $831 thousand from $746 thousand in the year-ago quarter. Net sales in Q3, 2017 were $957 thousand.

Net loss in the recent fourth quarter was $7.14 million or $10 per share compared to a net loss of $2.90 million or $133.36 per share in the year-ago quarter.

The Company ended the year 2017 with cash of $15.59 million.

5. Daxor Corporation (DXR)

Lost 14.69% to close Tuesday's trading at $11.85.

News: No news

The Company manufactures and markets FDA-cleared BVA-100 blood volume analyzer, which is used in conjunction with a single-use diagnostic kit.

Recent news:

-- On Mar.14, 2018, the Company announced new data from its study showing that patient care individualized by its Precision Blood Volume Analysis (BVA) reduces heart failure readmissions by 56% and mortality by over 80%. The stock rose as much as 62% that day to touch $8.10 in intraday trading. The following day, the stock gained another 177% to touch an intraday high of $21.66 on Mar.15, 2018.

6. Xtant Medical Holdings Inc. (XTNT)

Lost 11.38% to close Tuesday's trading at $8.64.

The Company is focused on developing regenerative medicine products and medical devices for domestic and international markets.

News: No news

Recent event:

-- On February 15, 2018, the Company announced that it had regained compliance with the NYSE American listing standards, with a positive stockholders' equity of approximately $47.4 million on a pro forma basis.

Upcoming event:

The Company is yet to report fourth quarter 2017 financial results.

7. Dicerna Pharmaceuticals Inc. (DRNA)

Lost 11.16% to close Tuesday's trading at $11.14.

News: No news

Clinical Trials & Near-term Catalysts:

-- A phase I clinical trial of DCR-PHXC for the treatment of primary hyperoxaluria is underway, with human proof-of-concept data expected in the second half of 2018.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT